GlaxoSmithKline
Dr Denis Martin
Chief of Molecular Biology
GlaxoSmithKline

The most important supplier of vaccines in Canada, GlaxoSmithKline has invested more than fifty million dollars in its North American headquarters located in Laval. The Laval scientists will conduct research and development of the following fields: adjuvants, molecular biology, immunology, vaccines targeting respiratory viruses, oncology and allergies as well as developing key processes. This major development for patients allows GSK Biologicals to offer a broader line of innovative vaccines that increase not only the quality of life of Canadian citizens but also those of other countries world wide. GSK is employing over 3300 people in Canada including 1400 in Quebec and its investments in research and development together with pharmaceutical products have reached two hundred million dollars.

Past Recipients